The UK's most complete GLP-1 guide
Every Question Answered. Every Side Effect Explained.
- How GLP-1 medications work
- Mounjaro vs Wegovy compared
- Injection instructions
- Side effects & solutions
- What to eat on treatment
- FAQs answered
Free tracker included with every download this week
Mounjaro Long-Term Side Effects — What You Need to Know
Mounjaro (tirzepatide) is a prescription-only GLP-1 and GIP receptor agonist approved in the UK for weight management. While most side effects occur in the first few weeks, questions about long-term safety are important. This guide covers what the MHRA has approved, ongoing monitoring requirements, and what evidence shows about extended use beyond the initial 12-week adjustment period. If you're considering Mounjaro via NHS specialist services or private prescription, understanding potential long-term effects helps you make an informed decision with your GP or prescriber.
10,000+ calculations today · NHS-aligned thresholds · 100% free
Calculate Your BMI Instantly
Enter your height and weight below. Supports both imperial (stone & lbs) and metric (kg). Results include NHS category, healthy weight range, and ethnicity adjustments.
What Is BMI and Why Does It Matter?
Body Mass Index (BMI) is the most widely used screening tool for assessing whether your weight falls within a healthy range. Used by the NHS, GPs, and weight management services across the UK, BMI provides a quick snapshot of your weight relative to your height. The formula is simple: your weight in kilograms divided by your height in metres squared (kg/m²).
While BMI isn't a perfect measure — it doesn't account for muscle mass, bone density, or fat distribution — it remains the standard first step in identifying potential weight-related health risks including type 2 diabetes, cardiovascular disease, high blood pressure, and certain cancers.
The NHS also recommends adjusted thresholds for people of South Asian, Chinese, or Black African heritage — a BMI of 23 or above is classified as overweight, and 27.5 as obese. Our calculator includes this adjustment as a one-click toggle.
Long-Term Safety Data and MHRA Monitoring
Mounjaro carries MHRA Black Triangle (▼) status, meaning it is subject to additional monitoring for safety signals. The longest published clinical trial data (SURMOUNT-1) followed participants for 72 weeks, showing that most side effects stabilise or improve after the initial dose escalation phase.
Common long-term concerns include:
- Pancreatitis risk: Rare but serious; persistent upper abdominal pain requires immediate medical attention and GP consultation
- Gallbladder complications: gradual weight management may increase gallstone risk — monitored but not preventable
- Thyroid changes: Animal studies showed thyroid issues; human long-term data is still emerging
- Retinopathy (eye changes): In people with existing diabetes, vision changes must be reported to your GP immediately
- Gastroparesis worsening: Long-term gastric slowing may affect nutrient absorption
The MHRA requires ongoing pharmacovigilance reports from prescribers. If you experience new symptoms after 12+ weeks on Mounjaro, contact your GP or prescriber — do not adjust your dose without guidance.
Clinically BackedWeight Loss
No appointments. No waiting rooms. Just care — from a UK-regulated online pharmacy.
How It Works
Three simple steps to understand your weight and take action.
Enter your height and weight in our free calculator. Get your BMI, NHS category, healthy weight range, and ethnicity-adjusted thresholds instantly.
If your BMI suggests you're overweight or obese, explore our GLP-1 calculators to project potential weight loss on Mounjaro or Wegovy.
Use our progress tracker to log your weight weekly, visualise your journey with charts, and stay motivated — all stored privately in your browser.
Free Weight Loss Tools & Guides
Everything you need to understand your weight, explore medication options, and track your progress — completely free.
Eligibility and NHS vs Private Prescribing Context
In the UK, Mounjaro eligibility requires a BMI of 30 kg/m² or above, or 27–29.9 with weight-related health conditions (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, or cardiovascular disease). NHS access is through tier 3 specialist weight management services — not routine GP prescription — and involves formal clinical assessment including baseline blood work and ongoing monitoring.
Private prescribing via online clinics requires similar clinical assessment but faster access. Either route means your prescriber monitors you throughout treatment. Long-term side effect discussions should happen at your initial assessment and at each dose titration step. Our GLP-1 weight loss calculator can help you understand potential benefits relative to risks, and use our BMI calculator to check whether you meet NHS eligibility thresholds in your region.
Stopping Mounjaro does not reverse long-term side effects instantly — some effects like gallstone formation or metabolic changes persist. Weight regain typically begins within weeks of stopping. The decision to continue beyond 1–2 years is individualised; your prescriber will review ongoing safety and benefit. If you develop persistent stomach pain, vision changes, heart palpitations, or signs of pancreatitis (severe upper abdominal pain radiating to the back), seek urgent medical care and inform your healthcare provider you are taking Mounjaro.
- Dual GIP/GLP-1 receptor agonist
- Up to 22.5% body weight loss (SURMOUNT-1)
- Weekly injection, dose escalation over 20+ weeks
- Available via private prescription in the UK
- Doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- GLP-1 receptor agonist
- Up to 15–17% body weight loss (STEP trials)
- Weekly injection, 5-step dose escalation
- NHS & private prescription available
- Doses: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Mounjaro vs Wegovy: Head-to-Head
A side-by-side comparison of the two most popular GLP-1 weight loss medications available in the UK.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Active ingredient | Tirzepatide | Semaglutide |
| Avg. weight loss | 15–22.5% | 12–17% |
| Key trial | SURMOUNT-1 (2022) | STEP 1 (2021) |
| Max dose | 15 mg weekly | 2.4 mg weekly |
| Escalation period | 20–32 weeks | 16–20 weeks |
| Administration | Weekly injection (pen) | Weekly injection (pen) |
| NHS availability | Private prescription only | NHS & private |
| Approx. private cost | £150–£250/month | £150–£300/month |
| Common side effects | Nausea, diarrhoea, constipation | Nausea, vomiting, diarrhoea |
Data sourced from SURMOUNT-1 and STEP 1 clinical trials. Costs are approximate and vary by provider. Always consult a prescriber.
Am I Eligible for Weight Loss Medication?
In the UK, eligibility for GLP-1 weight loss medications like Mounjaro and Wegovy is based on your BMI and overall health profile.
- BMI of 30 or above (obese)
- Age 18 or over
- No contraindicated conditions
- Committed to lifestyle changes
- BMI of 27 or above
- Plus type 2 diabetes
- Or high blood pressure
- Or obstructive sleep apnoea
Use our BMI calculator to check whether your BMI falls within the eligible range.
How We Built These Tools
Every calculator and guide on myweightcheck is built with accuracy and transparency in mind. Our BMI calculator uses the standard WHO formula with NHS-aligned category thresholds. Our GLP-1 projections are modelled on published clinical trial data from SURMOUNT and STEP studies.
All data stays on your device. We don't require sign-ups, and we don't store your health information on any server. Your progress tracker saves data locally in your browser using localStorage, so only you can see it.
We're based in the UK and our tools are designed specifically for UK users — supporting stone & lbs by default, referencing NHS guidelines, using NICE-approved medication data, and linking to GPhC-registered pharmacies.
Frequently Asked Questions
Common questions about BMI, weight loss medications, and our free UK tools.
Are there long-term side effects of Mounjaro that don't show up immediately?
Most Mounjaro side effects appear in the first 4–8 weeks and stabilise by 12 weeks. Rare long-term risks include pancreatitis, gallstone formation, and thyroid changes — monitored by the MHRA. Extended trial data beyond 72 weeks is still being collected, so ongoing vigilance is important. Always report new symptoms to your GP or prescriber.
How does the MHRA monitor Mounjaro for long-term safety?
Mounjaro has Black Triangle (▼) status, requiring additional safety monitoring. Prescribers submit adverse event reports; the MHRA reviews safety signals continuously. If new long-term risks emerge, the MHRA will update guidance and inform healthcare professionals and patients. This is standard for newer weight loss medications.
Can long-term Mounjaro use affect fertility or pregnancy?
Mounjaro is not recommended during pregnancy or while breastfeeding. Women of childbearing age should use contraception; oral contraceptive effectiveness may be reduced for 4 weeks after starting and after each dose increase. Discuss pregnancy plans with your GP or prescriber before starting Mounjaro.
What happens to side effects if I stop Mounjaro after a year or more?
Gastrointestinal side effects (nausea, constipation, diarrhoea) usually resolve within 1–2 weeks of stopping. However, structural changes like gallstones or metabolic adaptations persist. Weight regain typically begins within weeks. Your prescriber will discuss long-term management before you stop treatment.
Should I have blood tests while on Mounjaro long-term?
Yes. Your prescriber will arrange baseline blood work before starting and may recommend periodic monitoring, especially if you have diabetes, kidney issues, or other comorbidities. Regular GP check-ups are important to catch any emerging side effects early. Always report symptoms between scheduled appointments.
Ready to take control of your weight loss journey?
Start with a free BMI check, explore your GLP-1 options, or begin tracking your progress today. No sign-up. No cost. Just results.